Endometriosis Pain & Cannabis: What Recent Studies Show

Overview of Recent Peer‑Reviewed Findings

All studies cited below were indexed in PubMed, the U.S. National Library of Medicine’s database of peer‑reviewed research. They represent the current, evidence‑based understanding of how cannabis and related therapies might interact with endometriosis and pelvic pain. These findings are for educational purposes only; they do not replace individualized medical advice.

1. Cellular Effects of Phytocannabinoids on Endometrial Tissue

A 2025 study in Reproductive Toxicology examined how several phytocannabinoids—cannabidiol (CBD), cannabichromene (CBC), cannabidivarin (CBDV), cannabigerol (CBG), and cannabinol (CBN)—affect endometrial stromal cells (ESCs) in the menstrual cycle. The researchers treated cultured ESCs with each compound and measured changes in cell proliferation, differentiation, and senescence markers. They found that all five cannabinoids modulated these cellular processes, suggesting that the endocannabinoid system may play a role in normal endometrial function and, potentially, in disorders such as endometriosis (see PubMed: 40706771).

2. Patient‑Reported Impact of Medicinal Cannabis on Pelvic Pain

In a prospective cohort study published in BMC Complementary Medicine and Therapies, researchers followed 120 adults with endometriosis who used medicinal cannabis for at least three months. Participants completed questionnaires on pain intensity, dysmenorrhea, fatigue, and quality of life. The study observed that many users reported reductions in pelvic pain and improved daily functioning. However, the authors noted that the evidence remains observational, and larger randomized trials are needed (PubMed: 41566248).

3. Feasibility of a Randomized Controlled Trial in Australia

Another Australian study, published in Complementary Therapies in Clinical Practice, explored the practicality of conducting a randomized controlled trial (RCT) comparing inhaled medicinal cannabis (16% Δ9‑tetrahydrocannabinol) and a CBD‑dominant product against placebo in women with endometriosis. The trial faced recruitment challenges and variable dosing adherence, leading the investigators to conclude that while the concept is feasible, logistical and ethical hurdles must be addressed before a full RCT can be implemented (PubMed: 41005282).

4. Expert Review of Cannabis Use in Endometriosis Management

A review article in Expert Review of Endocrinology & Metabolism surveyed existing cross‑sectional and retrospective data on cannabis use among women with endometriosis. The authors highlighted that many patients report using cannabis to alleviate pain and other symptoms, yet robust clinical evidence is scarce. They discussed potential mechanisms—such as modulation of inflammatory pathways and pain signaling—while emphasizing the need for high‑quality RCTs before drawing firm conclusions (PubMed: 41070712).

5. Light Therapy as a Novel Pain Modulator in a Mouse Model

In a preclinical study published in Reproductive Sciences, researchers investigated whether exposure to green light‑emitting diodes (gLED) could reduce endometriosis‑associated pain in mice. They induced deep endometriosis in 16 female mice and then exposed one group to gLED (520–525 nm) daily, while a control group received white LED light. Pain behaviors were assessed over four weeks. The gLED group showed a significant decrease in pain responses compared to controls, suggesting a potential non‑pharmacologic adjunct for pain management (PubMed: 41854839).

6. Survey on Cannabis Use, Safety, and De‑Prescribing Trends

In a large international survey involving 889 respondents, an article in the Australian & New Zealand Journal of Obstetrics & Gynaecology examined self‑reported effectiveness, safety, and trends in de‑prescribing other medications when cannabis was used for endometriosis. The study found that many participants felt cannabis helped with pain and reduced reliance on other pain medications, yet reported variable side effects. The authors called for more systematic safety evaluations (PubMed: 41249881).

Key Take‑Away Points

• Phytocannabinoids can influence cellular processes in endometrial tissue, which may have relevance for endometriosis biology.
• Patient reports suggest possible pain relief with medicinal cannabis, but controlled trials are limited and inconclusive.
• Logistical challenges exist when designing rigorous clinical studies for cannabis therapies in endometriosis.
• Non‑medical interventions, such as green LED light exposure, are emerging as potential adjuncts for pain control in preclinical models.
• Safety and de‑prescribing data indicate variable experiences; ongoing research is essential.

What This Means for You

These studies collectively indicate that the relationship between cannabis and endometriosis pain is complex and not yet fully understood. The evidence is evolving, and no single study provides definitive guidance on efficacy or safety. If you are considering medical cannabis, it is important to discuss it with a licensed healthcare provider who can help you weigh potential benefits against risks and coordinate with your existing treatment plan.

Next Steps

Stay informed about new research, ask your physician about current evidence, and consider whether a trial of medical cannabis—under professional supervision—might fit your health goals. Compassionate Alternative Care is here to answer questions and provide reliable information, but it cannot replace personalized medical advice.